Alnylam today announced the addition of RNA interference therapies for the hepatitis delta virus and chronic liver infections to its clinical pipeline at the American Association for the Study of Liver Diseases in Boston. The company also said it remains on track to select a candidate for its hepatitis B program by the end of the year and hopes to file an investigational new drug application with the FDA in late 2015.
BOSTON--Talking of breaking internal silos has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKline's ($GSK) head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference. Read more >>
The prospects for Remoxy, the twice-rejected, investigational, extended-release oral formulation of oxycodone, look bleak. Pfizer is pulling out of a partnership with Durect to commercialize the candidate, after reviewing the results of 5 clinical trials conducted in response to the FDA's second complete response letter, issued in 2011. Read more >>
POPULAR COMMENT THREADS
Researchers at the University of California in San Diego have developed a way to disguise the genetic material itself so that it can enter cells and shut down genetic diseases at the core.
Arrowhead Research reported a net loss of $58.7 million in fiscal year 2014, up from $31.7 million in FY 2013.
Combining diagnostics and drug delivery is an ideal progression to improve the effectiveness and speed of treatment and a way to make drugs "smarter." To make one of these two-in-one systems, Singapore-based researchers developed a new biomarker that lights up to locate tumors and releases cancer drugs at the same time.
Pfizer's partnership with German counterpart Merck KGaA for $850 million upfront, plus as much as $2 billion in milestones, improves the prospects of PD-L1 and PD-1 checkpoint inhibitors in the oncology space, to the excitement of developers of combination therapies to the class of medicines, which feature both biological and mechanical mechanisms.
Researchers have developed a delivery vehicle that could help push DNA vaccines--those based on a small part of a microbe's genes--into a more prominent position and possibly into the market down the road.
Patients are overconfident in their ability to operate drug delivery medical devices and may not realize that they are using them incorrectly, a comprehensive survey by the U.K.'s Team Consulting shows.
From Our Sister Sites
Welcome to the latest edition of our weekly EuroBiotech Report. Chiesi and UnIQure have raised the bar for rare drug prices, setting the tone for the blossoming gene therapy sector in the process....
The FDA has slapped down Bristol-Myers Squibb's closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail strategy.